Investing.com - Needham lowered its price target on Amphastar Pharmaceuticals (NASDAQ:AMPH) to $30 from $34 while maintaining a Buy rating following the company’s fourth-quarter results. Despite the ...

Net Revenues: $719.9 million for the full year. BAQSIMI Revenue: $185.4 million, up 12% year over year. Primatene Mist Revenue: $108.7 million, up 7% year over year. Iron Sucrose Revenue: $4.4 million ...

Amphastar Pharmaceuticals (AMPH) reported $183.11 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 1.8%. EPS of $0.73 for the same period compares to $0 ...

Management explicitly guided to lower gross margins in 2026, attributing the pressure to "continued pricing pressure on glucagon, epinephrine, and phytonadione, which are high-margin products," and ...

Amphastar Pharmaceuticals reported its fourth-quarter 2025 earnings, revealing a significant miss in both earnings per share (EPS) and revenue compared to analyst forecasts. The company’s EPS came in ...

Shares of United Therapeutics climbed after the company said it planned to release a new soft mist inhaler to treat certain lung diseases next year. The stock rose 9%, to $515.94, midday Wednesday and ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

Brad Reese, the grandson of the inventor of Reese's Peanut Butter Cups, is criticizing The Hershey Co. for "quietly replacing" the candy's flagship chocolate and peanut butter ingredients. Reese ...